Literature DB >> 14991761

Modulation of prostate cancer growth in bone microenvironments.

Magnus Edlund1, Shian-Ying Sung, Leland W K Chung.   

Abstract

Bone remains one of the major sites, and most lethal host organs, for prostate cancer metastasis. Prostate cell spread and establishment in bone depends on multiple reciprocal modifications of bone stromal and epithelial cancer cell behaviors. This review focuses on recent advances in the characterization of cell-cell and cell-matrix interplay, effects on cell growth, adhesion and invasion, and several therapeutic possibilities for co-targeting prostate cancer cells and bone stroma. We address the topic from three main perspectives: (1) the normal and aging bone stromal environment, (2) the "reactive" bone stromal environment, and (3) the cancerous prostate epithelial cells themselves. First, normal, and especially aging, bones provide uniquely rich and "fertile soil" for roaming cancer cells. The interactions between prostate cancer cells and insoluble extracellular matrices, soluble growth factors, and/or sex steroid hormones trigger bone remodeling, through increased osteoclastogenesis and furthur matrix metalloproteinase activity. Second, after cancer cell arrival and establishment in the bone, host stromal cells respond, becoming "reactive" in a process again involving extracellular matrix remodeling, together with growth factor and steroid receptor signaling this process ultimately enhances cancer cell migration, stromal transdifferentiation, and invasion of the cancer tissues by stromal, inflammatory, and immune-responsive cells. Third, prostate cancer cells also respond to supportive bone microenvironments, where soluble and matrix-associated molecules affect cancer cell growth and gene expression, especially altering cancer cell surface receptor and integrin-mediated cell signaling. We discuss both integrin cell-matrix and gap junctional cell-cell communication between cancer cells and their microenvironments during prostate cancer progression. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14991761     DOI: 10.1002/jcb.10702

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  33 in total

Review 1.  Nitric oxide and cancer therapy: the emperor has NO clothes.

Authors:  Jason R Hickok; Douglas D Thomas
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

2.  Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype.

Authors:  Amrita Singh; Carmine Fedele; Huimin Lu; Marja T Nevalainen; James H Keen; Lucia R Languino
Journal:  Mol Cancer Res       Date:  2016-07-20       Impact factor: 5.852

Review 3.  Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes.

Authors:  Valentina R Minciacchi; Michael R Freeman; Dolores Di Vizio
Journal:  Semin Cell Dev Biol       Date:  2015-02-23       Impact factor: 7.727

Review 4.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

5.  Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro.

Authors:  Shona H Lang; Elizabeth Anderson; Robert Fordham; Anne T Collins
Journal:  Stem Cells Dev       Date:  2010-04       Impact factor: 3.272

6.  Tumor microenvironment promotes dicarboxylic acid carrier-mediated transport of succinate to fuel prostate cancer mitochondria.

Authors:  Aigul Zhunussova; Bhaswati Sen; Leah Friedman; Sultan Tuleukhanov; Ari D Brooks; Richard Sensenig; Zulfiya Orynbayeva
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

7.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

8.  Platelets govern pre-metastatic tumor communication to bone.

Authors:  B A Kerr; N P McCabe; W Feng; T V Byzova
Journal:  Oncogene       Date:  2013-09-15       Impact factor: 9.867

9.  Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Authors:  Fraser Conrad; Xiaodong Zhu; Xin Zhang; Robert J Chalkley; Alma L Burlingame; James D Marks; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2009-02-14       Impact factor: 4.599

Review 10.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.